FIELD: biotechnology.
SUBSTANCE: in the present invention, antibodies are presented, which specifically bind to human FAM19A5, as well as nucleic acid encoding an antibody, an expression vector, a cell for antibody expression, a composition for inhibition of FAM19A5 activity, a kit for inhibition of FAM19A5 activity, a method for the production of an antibody, which specifically binds to human FAM19A5 protein, and a method for the treatment of disorders, such as damage to the central nervous system, degenerative brain disease, or neuropathic pain, by administration of an antibody, which specifically binds to human FAM19A5.
EFFECT: obtainment of an antibody against human FAM19A5.
37 cl, 25 dwg, 9 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR AND APPLICATION THEREOF | 2019 |
|
RU2778023C1 |
| NEW ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION | 2018 |
|
RU2805674C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTIBODY FOR SPECIFIC BINDING TO N-TERMINAL DOMAIN OF LYSYL-TRNA SYNTHETASE EXPOSED ON EXTRACELLULAR MEMBRANE | 2019 |
|
RU2781304C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
